

Collin A. Hovinga, PharmD., M.S., FCCP

Office Address: 9211 Corporate Blvd, Suite 260, Rockville, MD 20850

Mailing Address: 16408 Pallazo Dr., Pflugerville, TX 78660

collin.hovinga@iactc.org

EDUCATION

Masters of Science in Epidemiology *Magna cum laude* 2010

University of Tennessee Health Science Center,
Memphis, TN.

Doctor of Pharmacy, *Summa cum laude* 1997

Creighton University, School of Pharmacy and Allied Health
Professions, Omaha, NE.

Bachelor of Science in Biology, *Magna cum laude* 1991

Creighton University, College of Arts and Sciences,
Omaha, NE.

POSTDOCTORAL TRAINING

Health Outcomes and Economics Fellowship 2012-2013

MD Anderson Cancer Center and University of Texas Southwestern,
Houston, TX.

Pediatric Clinical Pharmacology Fellowship July 2009

Office of Clinical Pharmacology
U.S. Food and Drug Administration (FDA), Silver Springs, MD.

Pediatric Pharmacotherapy Fellowship July 1998-June 2000

NIH Pediatric Pharmacology Research Unit
University of Tennessee, Memphis, TN.

Pediatric Pharmacotherapy Residency July 1997-June 1998

University of Tennessee, Memphis, TN.

PROFESSIONAL EXPERIENCE

Senior Vice President, Clinical and Scientific Development 2018-present

The Institute for Advanced Clinical Trials for Children (I-ACT)

Director of Research Support Services 2015-2018

Ascension Hospitals Texas and Seton Healthcare Family Austin

Director of Research and Research Integrity 2011-2015

Dell Children's Medical Center, Pediatric Surgical Subspecialists

Director of the Neuropharmacology Translational Research 2006-2011

Laboratory

Le Bonheur Children's Medical Center, Division of Clinical

Pharmacology

Associate Director of Research and Neuropharmacologist Miami Children's Hospital Research Institute	2003-2006
Neuropharmacology Specialist, Research Manager Cleveland Clinic Foundation	2000-2003
Pharmacist Le Bonheur Children's Medical Center	1997-1999

ACADEMIC APPOINTMENTS

Clinical Associate Professor of Pharmacy University of Texas at Austin, College of Pharmacy	2011-present
Associate Professor of Pharmacy and Pediatrics University of Tennessee Health Science Center, College of Pharmacy	2011
Assistant Professor of Pharmacy and Pediatrics University of Tennessee Health Science Center, College of Pharmacy	2006-2011
Assistant Professor of Neurosurgery University of Miami School of Medicine, Department of Neurosurgery	2003-2006
Adjunctive Mentor Faculty Creighton University, School of Pharmacy and Allied Health Professions	2001-2005
Assistant Professor Creighton University, College of Arts and Science, Department of Biology	1990-1991

MEMBERSHIPS AND AFFILIATIONS

Multi-Regional Clinical Trial Center Working Group-Promoting Global Clinical Research in Children Active Member	2019-present
Collaborative Network for European Clinical Trials for Children (Conect 4 Children) U.S. Representative, International Global Pediatric Interoperability Committee	2018-present
Expert Advisory Committee (WP4)	2018-present
Education and Training Committee (WP6)	2018-present
Vice Chair, External Advisory Committee	2018-present
Enpr-EMA-FDA Working Group on International Collaboration U.S. Representative	2018-present
The International Children's Advisory Network (iCAN)	2017-present

Member, Medical Advisory Board	
Pfizer, Inc., Groton, CT	2016-2017
Founding Member, Pfizer External Expert Panel (PEEP)	
American College of Clinical Pharmacy	1997-present
Member, 2018 Pediatric Pharmacy Standard Setting Panel	2017-2019
President Elect, Advisory Committee, National Practice Based Research Network	2015
Member, Practice Based Research Committee	2013-2017
Member, Resident/Fellow Core Curriculum Committee	2013-2014
Advisory Committee, National Practice Based Research Network	2012-2018
Secretary Treasurer, Central Nervous System Practice and Research Network	2011-2012
Member, Annual Program Committee 2012	2010-2012
Member, Virtual Committee Advisory Committee	2008-2009
Member, Educational Committee B	2007-2008
Acting Chair, Central Nervous System Practice and Research Network	2006-2007
Chair Elect, Central Nervous System Practice and Research Network	2005-2006
Member, Research Affairs Committee	2002-2006
Member, Industrial Relations Committee	1999-2000
Pediatric Pharmacy Advocacy Group	1997-2017
Board Review Faculty-Neurology/Psychiatry	2015-2017
PRN Journal Advisor and Reviewer	1997-present
American Epilepsy Society	2000-present
Member, Allied Health Professionals	2008-2011
Member, Clinical Therapeutics Committee	2004-2008
Member, Practice Committee	2001-2006
Texas State Autism Spectrum Disorders, Austin, TX	2014-2015
Medical Advisory Committee, Planning Committee	
Tuberous Sclerosis Alliance, Silver Springs, MD	2014-present
Medical and Scientific Advisory Committee	
U.S. Food and Drug Administration, Silver Springs, MD	2012-2015
Special Government Employee, Peripheral and Central Nervous System A.C.	
Seton Healthcare Family, Austin, TX	2012-2015
Member, Institutional Review Board	
Children's Optimal Health, Austin, TX	2012-2017
Technical Advisory Committee	
American Academy of Neurology	
Member, Pregnancy and Lactation Position Paper	2005-2007
Chair, Folate use, lactation/placental transfer, Vitamin K use	
Co-chair, Pharmacokinetics	

American Society of Health-System Pharmacists	1996-2000
Phi Lambda Sigma National Pharmacy Leadership Society	1996-present
Rho Chi National Honor Society	1995-present
Vice President	1995-1996

HONORS AND AWARDS

Fellow, American College of Clinical Pharmacy	2011
Volunteer Leader Recognition, American Epilepsy Society	2005-2009
Research Sabbatical, American College of Clinical Pharmacy	2001
Dean's Honor Award, Creighton University	1994-1995
Rho Chi Academic Achievement Award	1994
State of Iowa Scholar	1991
Outstanding Chemistry/Biology Student Award	1991
Dean's List Creighton University	1987-1997
Reinhart Condon Academic Scholarship	1987

CONSULTANCIES AND ADVISORY ACTIVITIES

Patient Advocacy

Firefly Fund for Niemann-Pick disease type C1 (NPC1) 2017-present

Member, Scientific Advisory Board

Healthcare Advisor, Board of Directors

Working with state legislators to study the feasibility of neonatal testing, pipeline development and patient registry.

HydroAngels 2015-2016

Board of Directors

Research Director

Tennessee Epilepsy Foundation 2008-2011

Pharmacy and Advocacy

Autism Solution Center 2007-2008

Board of Directors

Private Not-for-Profit Research

Established Guidelines for Care, Standards for Preclinical and Clinical Trials

NIH-CTSA Standards for Informed Consent 2017-present

NIH Standard Data Elements for Research 2011-2012

AES/AAN Guidelines for Woman with Epilepsy Lead Pharmacokinetics, Drugs in Lactation, Vitamin Supplementation	2008-2009
Spinal Muscular Atrophy (SMA) Foundation	2005-2007
NIH/NINDS Huntington's Study Group –Drug Trials in Disease Modification Translational Research Consultant (CINAPS)	2005-2007
HiQ Foundation/MRSI, Psychogenics, Inc. Drug Evaluation Consultant	2003-2006
Pharmaceutical	
Questcor Pharmaceuticals Educational Consultant	2008-2010
UCB, Inc. Pharma-Speaker's Bureau	2001-2007
Johnson & Johnson PRD and OrthoMcNeil Consultant Trial Design for Epilepsy	2003-2006
GlaxoSmithKline, Inc. Consultant, Speaker's Bureau	2000-2004
Eisai Pharmaceuticals Consultant	2000-2003
Pfizer Consultant-Pediatric Hypertension Trial Design	1999-2000

EDITORIAL RESPONSIBILITIES

Lexicomp Drug Information and Handbooks Content Advisor, Neurology and Pediatrics	2003-present
Cochrane Review-Epilepsy Group, Liverpool, UK Author-Reviewer	2010-2011

CLINICAL PRACTICE

Certification and Licensure

Pharmacist, State of Tennessee, No. 0000010144, Exp. 7/31/2021	Active
Pharmacist, State of Texas, No. 51309, Exp. 11/30/2021	Active
Immunization Certification, American Pharmaceutical Association	Active
Citi Training Biomedical Research, IRB Member/Chair, GCP	Active

Clinical Innovations and Quality Improvement Projects

Project Mentor, Seton Family Hospitals Quality and Health Outcomes	2013-2018
--	-----------

Program, Austin, TX

“Improving Infectious Disease Isolation Practices in General Medicine Floor.”

“Improving Outcomes and Clinical Workflow in Spasticity Clinic.”

“Maximization of Concussion Workflow and Patient Related Value.”

“Factors that Influence Shunt Longevity in Hydrocephalic Patients.”

“Decrease Waste in Operative Material Use.”

“Epilepsy Surgical Evaluations-Implementation of a Practice Guideline Based Referral System.”

GRANTS

FDA Grants

FDA U18FD006297 **I-ACT for Children The Development of a Global Pediatric Clinical Trials Network.** Co-Principal Investigator. 2017-current

NIH Grants – Completed

NINDS NS065818-01A1 **Thrombolysis in Pediatric Stroke (TIPS) grant.** Co-Investigator. Study, Director of the Pharmacokinetic Core. 2011-2014

NINDS/HiQ Foundation. **Systemic Evaluation of Treatments for Huntington’s Disease,** Consultant, Co-Chair. 2004, Chair- 2005-2006. 2004-2006

NINDS NS5045911/NS5045803 **Childhood Absence Epilepsy: Rx PK-PD-Pharmacogenetics.** Co-Investigator. 2004-2006

NIH/NINDS **Committee to Investigate Neuroprotective Studies in Parkinson's (CINPAPS),** Consultant (Subcontract), Member Neuropharmacology Advisory Board. 2002-2004

Institutional Research Grants

Inaugural UTHSC Clinical Translational Science Institute K12 Scholar Grant (CTSI) **Identification of Genes Modulating Susceptibility with Neonatal Hypoxia-Induced Seizures (HIS).** 2008-2011

Le Bonheur Small Grant. **Differences in Inbred Strains and Seizure Susceptibility Following Hypoxia in Neonatal Mice.** Principal Investigator. 2008

University of Tennessee Health Science Center Seed Grant. **Development of A Mouse Model of Hypoxia Induced Seizures.** Principal Investigator. 2007-2008

Miami Children's Hospital Research Institute Seed Grants. **Efficacy of Lamotrigine in a Neonatal Model of Hypoxic-Ischemic Injury.** Principal Investigator. Aug. 2002-2004

American College of Clinical Pharmacy, CNS PRN. Neuroprotection in Neonatal Ischemia and Hypoxia. Research Mini-sabbatical on Model of Neonatal Ischemia and Hypoxia, and Immunohistochemistry Techniques. <u>Principal Investigator</u> . Mentor: Susan Fagan, PharmD, BCPS, FCCP., Professor of Neurology, Medical College of Georgia.	2002
Investigator Initiated	
Seizure Control and Quality of Life in Children after Vagal Nerve Stimulator Placement, Corpus Callosotomy or Ketogenic Diet Initiation. Sander Foundation <u>Co-Investigator</u> .	2014-2018
Special Needs Assessment and Plan Study (SNAP). <u>Co-Investigator</u> .	2014-2018
A Randomized Controlled Trial of Cognitive Behavioral Therapy and Hypnotherapy to Manage Pain in Pediatric Patients with Gastrointestinal Disease. <u>Co-Investigator</u> .	2014-2018
Evaluation of an Innovative Model of Care for Children with Complex Medical Needs. Seton Innovations Grant. <u>Co-Investigator</u> .	2014-2018
Efficacy of Sonicare Tooth Brush on Oral Hygiene for Cleft Palate and Lip in Patients 4-10 Years Old. Proctor and Gamble. <u>Co-Principal Investigator</u> .	2013-2017
Texas Survey of Best Practices in Epilepsy. <u>Co-Investigator</u> .	2012-2013
IV Lacosamide: The Safety of Intravenous Lacosamide. Shainberg Fund. <u>Co-Investigator</u> .	2009-2012
Genetic Susceptibility in Neonatal Hypoxia Induced Seizures-QTL Analysis. Le Bonheur Children's Medical Center Grant. <u>Principal Investigator</u> .	2008-2009
Development of a Neonatal Seizure Model of Hypoxia-Induced Seizures. University of Tennessee College of Pharmacy Seed Grant. <u>Principal Investigator</u> .	2007-2008
Rapid Infusion of Levetiracetam in Pediatric Patients. Shainberg Fund. <u>Co-Investigator</u> .	2007-2008
Two-year Follow-up Study Evaluating the Efficacy of Levetiracetam in Adult and Pediatric Patients with Epilepsy. <u>Principal Investigator</u> . Funded UCB Pharma, Inc.	2002-2003
Pharmacokinetics of Lamotrigine in the Mother and the Neonate. <u>Principal Investigator</u> . Funding by GlaxoSmithKline.	2001-present
Post-Marketing Evaluation of Levetiracetam in Adult and Pediatric Outpatients. <u>Principal Investigator</u> . Funding UCB Pharma, Inc.	Feb. 2001-May 2001
Use of Lamotrigine in the Prevention of Epilepsy. <u>Principal Investigator</u> .	Feb. 2001-present

Funding GlaxoSmithKline.

Economic Evaluation of Parental Phenytoin Product Use in a Tertiary Hospital. Principal Investigator. Funding Pfizer Pharmaceuticals, Inc. Jan. 2001-2002

Pharmacokinetics of IV Valproate in Children with Epilepsy: A Preliminary Study, Principal Investigator, Funding Le Bonheur-University of Tennessee, Small Grant. Jul. 1998-Jul. 2000

Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital, Principal Investigator. Oct. 1998

Student vs. Preceptor Assessments During Fourth-Year Clinical Experiences, Principal Investigator. Jan. 1995

Private Industry. Clinical Drug Trials in Adults and Children (most therapeutic areas, emphasis in pediatrics and neurology). Private Industry supports 50 - 100 studies annually. Collaborating Investigator. 2000-2006

A 7-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effects of Adjunctive Levetiracetam on the Sleep Architecture of Adult Subjects (18-45 years of Age) with Partial Onset Epilepsy Receiving a First Generation Anti-epileptic Drug. Co-Investigator. Jun. 2002-2003

GlaxoSmithKline Inc., A Multi-center, Double-blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures. Co-Investigator. Oct. 2001-2003

UCB Pharma, Inc., A Double-blind, Multi-center, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Treatment with 3000 mg/day (pediatric target dose of 60 mg/kg/day) oral levetiracetam (LEV) (166, 20 and 500 mg tablets), in Adults and Pediatric Subjects (4-65 years) Suffering from Idiopathic Primary Generalized Tonic-Clonic (PGTC) Seizures. Co-Investigator. Sept. 2001-2003

OrthoMcNeil Pharmaceuticals, Inc. A Comparative Study of Topamax (Topiramate) Verses Depakote (Valproate) in Subjects with Juvenile Myoclonic Epilepsy. CAPSS-107. Co-Investigator. Feb. 2001-2003

GlaxoWellcome, Inc.. Open-Label, Uncontrolled Long-Term Study to Assess the Safety of Lamictal in Pediatric Subjects. LAM 20007. Co-Investigator. Jan. 2001-2003

GlaxoWellcome, Inc.: A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months) LAM 20006. Co-Investigator. Jan. 2001-2002

GlaxoWellcome, Inc. Open-Label, Multicenter, Randomized Trial to Dec. 2000-2003

Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects with Newly Diagnosed Epilepsy Initiating Anti-Epileptic Drug Treatment on either Lamotrigine or Valproate Monotherapy. <u>Co-Investigator</u> .	
Elan Pharmaceuticals, Inc. A Multicenter, Open-Label, Safety Study to Evaluate The Use of 25 mg and 50 mg Zonegran (Zonisamide) in the Initiation of Therapy in Patients With Epilepsy. <u>Co-Investigator</u> .	Dec. 2000-2001
Pfizer Pharmaceuticals: Pediatric Use of Amlodipine in the Treatment of Hypertension-2 Trial (PATH-2). A Population Pharmacokinetic Trial. <u>Principal Investigator</u> .	Dec. 1999-2000
Pfizer Pharmaceuticals: Pediatric Use of Amlodipine in the Treatment of Hypertension-I Trial (PATH-I). A randomized, double-blind, placebo-controlled, parallel group dose-ranging study to evaluate the efficacy and safety of amlodipine in the treatment of hypertension in children. <u>Co-Investigator</u> .	Dec. 1999-2000
Parke Davis: Gabapentin Pediatric Add-On Trial: A Randomize, Double-Blind Placebo Controlled, Parallel-Group, Multicenter Study in Patients With Partial Seizures, <u>Co-Investigator</u> .	Apr. 1999-Feb. 2000
Parke Davis: Open-Label, Safety Study of Gabapentin (CI-945) as Adjunct Therapy in Children Ages 1 Month Through 4 Years With Partial Seizures Uncontrolled by Current Anticonvulsant Drugs, <u>Co-Investigator</u> .	Mar. 1999-Jul. 2000
PPRU Network and UCSD: Evaluation of the Pharmacokinetics and Tolerance of Escalating Doses of Oral Pentoxifylline in Children with Acute Kawasaki Disease (IND# 48434), <u>Co-Investigator</u> .	Mar. 1999-Oct. 2000
Parke Davis: An Open Label, Safety, Tolerance, and Pharmacokinetic Study of Intravenous and Intramuscular Fosphenytoin (Cerebryx [®]) in Children < 5 Years of Age, <u>Co-Investigator</u> .	Apr. 1998-May 2000
Many others (>100s) as Co-Investigator-Areas of Neurology and Pediatrics.	Jul. 1997-1998

LOCAL COMMITTEE MEMBERSHIPS

The University of Texas at Austin

College of Pharmacy

Member, Curriculum Committee Interprofessional Education (IPE) Sub-Committee 2015-present

Member, Research Infrastructure and Lab Safety Committee 2015-present

Ascension Texas

Chair, Clinical Trials 2017-2018

Chair, Compliance Committee	2016-2018
Member, Legal Committee	2016-2018
Member, Finance Compliance Committee	2016-2018
Seton Family Hospitals	
Hospitals Research Operations Committee	2014-2018
Research Training and Education Committee	2014-2018
Dell Children's Medical Center	
Research Planning Committee	2012-2018
Seton Medical System	
Institutional Review Board Member	2012-2015
IT Infrastructure and Review Committee	2012-2018
University of Tennessee Health Science Center	
Clinical Research Center	
Member, Mentorship Committee	2009-2011
College of Pharmacy	
Member, Postdoctoral Association Committee	2007-2008
Member, Education Credentialing Committee	2007-2008
Member, Research Committee	2006
Cleveland Clinic Foundation-Case Western Reserve	
Member, Medical School Curriculum Committee	2002-2003
Cleveland Clinic Foundation	
Member, Neurology Intensive Care Steering Committee	2001-2003
Member, Pharmacy Department, Poison Prevention Committee	2001
University of Tennessee	
Member, Residency and Fellowship Review Committee	1999-2000
Creighton University School of Pharmacy and Allied Health Professions	
American Pharmacists Association Academy	
Member, Drug Information Committee	1993-1994
Creighton University School of Arts and Sciences	
Member, Biology Department, Curriculum Committee	1990-1991
Miami Children's Hospital	
Animal Research Committee/IACUC Committee	2004-2006
Cleveland Clinic Foundation	
Neurology Clinical Center for Research Task Force	2001-2003

EDUCATIONAL ACTIVITIES

Post Graduate Education

Seton Healthcare Family, Austin TX

Craniofacial Fellowship Course	2014-2018	
Pharmacy Residency Course	2014-2018	
Research Methods and Human Subjects Protection	Oct. 2013-2018	1 CH

Seton Healthcare Family, Austin TX

Research Methods and Human Subjects Protection	Oct. 2011, 2012	2 CH
--	-----------------	------

University of Texas Southwestern Medical School

Anticonvulsants and Psychiatry	Feb. 2013-2015	1 CH
Psychology Residency Program, Austin TX		
Management of Seizure Disorders	Oct. 2012, 2013	3 CH
Neurology Residency Program, Austin, TX		

Miami Children's Hospital, Miami, FL

Clinical Trial Design in Neurosciences	Nov. 2004, Sept. 2005	2 CH
Basic Neuropharmacology: Fellowship Course	Nov. 2004, Sept. 2005	2 CH

Cleveland Clinic Foundation, Cleveland, OH

Clinical Trial Design and Regulatory Issues, Laboratory	2001, 2002, 2003	2 CH
Neuropharmacology Lecture and Case Series	2001, 2002, 2003	6 CH
Neuropharmacology Weekly Teaching Rounds	Jan. 2001-2003	

Creighton University School of Pharmacy and Allied Health Professions

Functional Anatomy Web-based Instruction, Laboratory	2001, 2002, 2003	4 CH
General Physiology Web-based Instruction, Laboratory	Spring 2001	4 CH

Clinical Experiential Rotations

University of Texas at Austin, College of Pharmacy, Austin, TX

Pediatrics, Clerkship preceptor	2013-present	
---------------------------------	--------------	--

University of Tennessee, College of Pharmacy, Memphis, TN

Pediatric Neurology Pharmacokinetics/Neurology. Clerkship, preceptor	1997-2011	
Pharmacokinetics/Neurology. Clerkship, co-preceptor	1997-2011	
Parental Nutrition. Clerkship, co-preceptor	1997-2011	

Graduate Lectures

University of Texas at Austin, Dell Medical School

DMS 2020 Foundations in Interprofessional Collaborative Practice - Faculty Facilitator	2016-present	1 CH
---	--------------	------

University of Texas at Austin, College of Pharmacy

Special Populations

12SP/396D Clinical Pearls in Pediatrics	2012-present	1 CH
12SP/396D Special Dosing and Administration in Pediatrics	2012-present	1 CH
12SP/396D Fluid Replacement in Pediatrics	2012-present	1 CH
12SP/396D Pharmacokinetics and Pharmacodynamics in Pediatrics	2012-present	1 CH
12F Professional Development Convocation. Recitation/Lab	2012-present	1 CH
11F/695F Epilepsy, Pharmacotherapeutics III, Lecture	2012-present	6 CH

**DeBusk College of Osteopathic Medicine, Lincoln Memorial
University, Harrogate, TN**

Psychostimulant and ADD/ADHD Pharmacology, Neuroscience, Lecture	2007	1 CH
Antiepileptic Pharmacology, Neuroscience, Lecture	2007	2 CH

University of Tennessee, College of Pharmacy, Memphis, TN

Pediatrics Selective, Lecture, Case Discussion Brain Development and Neural Tube Defects / Pediatric Epilepsy-Pharmacotherapy	2008, 2009	2 CH
Therapeutics I. Ischemic and Hemorrhagic Stroke Lecture.	2008, 2009	3 CH
Neonatal Selective, Lecture, Case Discussion. Brain Development and Common Neurological Disorders / Neonatal Seizures	2007, 2008	2 CH
Neurology Selective, Lecture-Course Director.	2007	2 CH
Special Problems in Pharmacy, Pediatric Neurology Research, Projects Course	2006-2010	2 CH
Attention Deficit Hyperactivity Disorder. Applied Therapeutics V Lecture	2006-2010	4 CH
Autism. Applied Therapeutics V Lecture	2006-2010	4 CH
Introduction to Pharmacy and the Healthcare Environment, Recitation.	2006-2009	2 CH
Anticonvulsants, Applied Pharmacokinetics Lecture, Recitation.	1999, 2006	2 CH
Phenytoin. Applied Pharmacokinetics. Lecture	1998	2 CH
The Common Cold and Fever. Pediatric Selective Lecture	1998	1 CH
Diaper Rash, Thrush, and Fever. Pediatric Selective Lecture	1998	1 CH
Febrile Seizures. Pediatric Selective Lecture	1998-2000	1 CH
Antipyretics. Over-the Counter Medications Lecture	1998-2000	2 CH
Attention Deficit Hyperactivity Disorder. Pediatric Selective Lecture	1999-2000	2 CH
Congenital Heart Disease. Applied Therapeutics I Lecture	1998-1999	2 CH
Pediatrics. Therapeutics I Lecture/Clerkship	1997	2 CH
Epilepsy. Introduction to Therapeutics, Lecture	1997	1 CH

Undergraduate Courses

Creighton University, School of Arts and Science, Omaha, NE

Introductory Biology Laboratory, Lecture I	1991, 1992	1 CH
--	------------	------

ADVISING AND MENTORING

Graduate Education Research Mentorship

Kimberly Lewis, RN, MSN, PhD(c) –“ Factors Influencing Hyperlipidemia in Children with Juvenile Arthritis” The University of Texas at Austin, School of Nursing	2014-2016
Komal Gupte, PhD(c) – “The Cost of Refractory Epilepsy in Adults in Texas” The University of Texas at Austin, College of Pharmacy	2014
Brittany Wittenberg, PhD – “Special Needs Assessment and Plan (SNAP) Intervention in Children with Sensory Integration Disorder” The University of Texas at Austin, School of Human Ecology	2013-2016

Residents

Pharmacy Practice in Psychopharmacology and Medicine-Health Outcomes Research, The University of Texas Austin, College of Pharmacy Michelle Blair, PharmD.	2013
---	------

Doctor of Pharmacy

Pediatric Residency, Le Bonheur Children’s Medical Center, Memphis, TN	
Bess Flynn, PharmD.	2008-2009
Cynthia Hanson, PharmD.	2008-2009
Pratish Patel, PharmD.	2008-2009
Kerri Parks, PharmD.	2008-2009
Jessica Robinson, PharmD.	2008-2009
Megan Foster, PharmD.	2007-2008
Becky McGee, PharmD.	2007-2008
David Shoop, PharmD.	2007-2008
Emma Tillman, PharmD.	2007-2008
David Donald, PharmD.	2006-2007
Kelly Earhart, PharmD.	2006-2007
Curtis Petty, PharmD.	2006-2007
Jasmine Sahni, PharmD.	2006-2007
Chastity Sheldon, PharmD	2006-2007

Doctor of Medicine

Neuropharmacology-Neurology Fellow Cleveland Clinic, Cleveland, OH	
Tobias Loddenkemper, M.D.	2002-2003
Nadine Chehab PharmD.	2002-2003
Andreea Popas, PharmD.	2002-2003
Cornelia Drees, M.D.	2001-2002
Ajay Gupta, M.D.	2001-2002
Rhonda Rhea, PharmD.	2001-2002
Adria Serje, M.D.	2001-2002
David Lazdizabal, M.D.	2000-2003

EXTERNAL EDUCATIONAL ACTIVITIES: LOCAL GRAND ROUNDS/CONTINUING EDUCATION

Central Texas Epilepsy Foundation, Austin, TX Cannabinoids in the Treatment of Epilepsy.	Jan. 14, 2015
Annual Central Texas Dental Symposium, Austin, TX Top Pediatric Medications.	Apr. 19, 2013
Dell Children's Medical Center Epilepsy Symposium, Austin, TX Mechanisms of Action of Anticonvulsants From Bromides to Lacosamide.	May 7, 2012
Seton Hospital, Austin, TX. Neuropsychopharmacology and Epilepsy Anticonvulsant Teaching Course	Nov. 8, 2012 Oct. 7-10, 2012
MidSouth Epilepsy Support Foundation, Memphis, TN First and Second Generation Antiepileptic Drugs. Investigational Antiepileptic Medications: Introducing Them Into Practice.	Jun. 9, 2009 Feb. 10, 2009
Office of Clinical Pharmacology, FDA, Silver Springs, MD Translational Research in Neonatal Seizures.	Jun. 8, 2009
Middle and Western Tennessee Epilepsy Foundation, Annual Conference, Jackson, TN Medication Matters In Epilepsy.	Feb. 21, 2009
Dell Children's Medical Center Grand Rounds, Austin, TX Neonatal Seizures	Mar. 17, 2009
Le Bonheur Children's Medical Center Grand Rounds, Memphis, TN Pharmacology of Pediatric Epilepsy	Oct. 17, 2007
Ortho McNeil Pharmaceuticals, Miami, FL Pharmacokinetics of Anticonvulsants.	Jun. 4, 2004
Northeast Ohio Consultant Pharmacists, Elyria, OH Epilepsy in the Elderly.	Aug. 22, 2003
Elan Educational Conference. Cleveland, OH Practical Use of Zonigran.	Mar. 13, 2003
Cleveland Clinic Foundation Headache Staff Conference, Cleveland, OH Migraine Pharmacology.	Nov. 12, 2002
Pediatric Epilepsy Case Conference Bioactivation and Idiosyncratic Drug Reactions.	Nov. 6, 2002
GlaxoSmithKline CNS Preceptorship, Cleveland, OH Pharmacology of Headache and Migraine.	Oct. 31, 2002
Cleveland Clinic Foundation	

Epilepsy Grand Rounds: Drug Interactions and Epilepsy.	Oct. 25, 2002
Neurology Grand Rounds: Antiepileptogenic Drugs in Epilepsy.	Sept. 23, 2002
Epilepsy Postgraduate Course: Practical Guide to the New Anticonvulsants.	Sept. 9, 2002
Epilepsy Postgraduate Course: Pharmacology of the Traditional Anticonvulsants.	Sept. 8, 2002
Epilepsy Postgraduate Course: Research Design and Methods.	Sept. 6, 2002
Neurology Research Conference: Pharmacokinetics of Anticonvulsants in Neonates.	Jun. 7, 2002
Pediatric Neurology Grand Rounds: Overview of New Legislation Affecting Pediatric Drug Research (Is The Rule Dead?).	Jan. 14, 2002
Pharmacy Grand Rounds: Idiopathic Side Effects of the Newer Anticonvulsants: Relevance to Pediatric Patients.	Jan. 9, 2002
Pediatric Neurology Grand Rounds: Update on Lamotrigine Induced Rash: Time to Weigh the Evidence.	Jan. 7, 2002
Pediatric Grand Rounds: Bioactivation and Hypersensitivity Reactions in Epilepsy Across the Lifespan.	Nov. 5, 2002
Grand Rounds: Developmental Pharmacokinetic Pharmacokinetics Across the Lifespan.	Nov. 5, 2002
Pediatric Neurology-Epilepsy Teaching Conference: Monotherapy Trial Design in Refractory Epileptic Patients.	Oct. 21, 2001
Pediatric Noon Conference: Neuropharmacology 101 in Pediatric Patients: Part I.	Oct. 29, 2001
Review of The Monotherapy Trial Design Considerations in Epilepsy. OrthoMcNeil Pharmaceuticals. Cleveland Clinic Foundation, Cleveland, OH,	Sept. 27, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Antiepileptic Pharmacology in the PICU: Part II.	Jun. 27, 2001
Pharmacotherapy Update, Lecture Series. Antiepileptic Medications.	Jun. 25, 2001
Pharmacotherapy Update, Lecture Series. Antiepileptic Medications.	Jun. 11, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Antiepileptic Pharmacology in the PICU: Part I.	Jun. 6, 2001
Neuropharmacology Rounds: New Antiepileptic Medications	Apr. 25, 2001
Divisions of Pharmacy and Nursing Health Odyssey 2001: Through A Looking Glass: "New Antiepileptic Medications: A Practical Approach."	Apr. 23, 2001
Pediatric Neurology-Epilepsy Teaching Conference: Pharmacological Treatment of Nonconvulsive Status Epilepticus.	Mar. 16, 2001
Neuroprotective Properties of the Newer Antiepileptic Medications.	Feb. 23, 2001
Pharmacological Treatment of Nonconvulsive Status Epilepticus	Dec. 14, 2000
PICU Staff: Antiepileptic Pharmacology in the PICU.	Nov. 16, 2000
Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Feb. 10 & 24, 2000
OrthoMcNeil Pharmaceuticals CNS Preceptorship. Anticonvulsant Mechanisms and Therapeutic Uses.	Sept. 26, 2002
GlaxoSmithKline Preceptorship, Cleveland, OH Migraine Pharmacotherapy: Making Sense of All the Choices.	Nov. 5, 2002

Abbott Pharmaceuticals. Cleveland, OH Clinical and Basic Considerations in Neuropharmacology.	Dec. 14, 2001
Elan Pharmaceuticals, Cleveland, OH A Mechanistic Approach to Drug Interactions.	Nov. 17, 2001
University of Connecticut School of Pharmacy Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 10, 2000
University of Colorado Health Science Center Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 14, 2000
University of Tennessee School of Pharmacy Use of Intravenous Valproate in Generalized Convulsive Status Epilepticus.	Jan. 17, 2000
University of Tennessee and Tennessee Pharmacists Association 1999 Basic Pharmacology and Therapeutics: Common Pediatric Diseases.	Oct. 15, 1999
1999 Basic Pharmacology and Therapeutics: Attention Deficit Hyperactivity Disorder.	Oct. 15, 1999

PUBLICATIONS

Peer-reviewed publications

Cadmus SD, Sebastian KR, Warren D, **Hovinga CA**, Croce EA, Reveles LA, Levy ML, Diaz LZ. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study. *Pediatric Dermatology*. 2019; 36:437-41.

Gupte-Singh K, Wilson JP, Barner JC, Richards KM, Rascati KL, **Hovinga C**. Patterns of antiepileptic drug use in patients with potential refractory epilepsy in Texas Medicaid. *Epilepsy Behavior*. 2018; 87:108-16.

Zhu TH1, Werchan IA, Escamilla KV, Sebastian K, **Hovinga CA**, Reichenberg JS. Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use. *J Psychiatry Practice*. 2018; 24:428-431.

Pickel S, Shen MW, **Hovinga C**. Look Who's Talking: Comparing Perceptions Versus Direct Observations in Family-Centered Rounds. 2016; 6:387-93.

Wilkinson M, King B, Iyer S, Higginbotham E, Wallace A, **Hovinga C**, Allen C. Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. *Journal of Asthma*. 2017; 26:1-8.

Rivkin MJ, deVeber G, Ischord RN, Kirton A, Chan AK, **Hovinga CA**, Gill JC, Szabo A, Hill MD, Scholz K, Amlie-Lefond C. Thrombolysis in Pediatric Stroke study. *Stroke*. 2015; 46:880-5.

Bernard TJ, Rivkin MJ, Scholz K, deVeber G, Kirton A, Gill JC, Chan AK, **Hovinga CA**, Ichord RN, Scholz K, Grotta JC, Jordan LC, Benedict S, Friedman NR, Dowling MM, Elbers J, Torres M, Sultan S, Cummings DD, Grabowski EF, McMillan HJ, Beslow LA, Amlie-Lefond C. Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial. *Stroke*. 2014; 45:2018-23.

Krushkal J, Murphy LE, Palmer FB, Graff JC, Sutter TR, Mozhui K, **Hovinga C**, Thomas F, Park V, Tylavsky FA, Adkins RM. Epigenetic analysis of neurocognitive development at 1 year of age in a community practice based pregnancy cohort. *Behavior Genetics*. 2014; 44:113-25.

Ilo E and **Hovinga CA**. Extended-release antiepileptic drugs: A comparison of pharmacokinetic parameters relative to original immediate-release formulations. *Epilepsia*. 2013; 54: 28-35.

Harden CL, Pennell PB, Koppel BS, **Hovinga CA**, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:142-9.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:133-41.

Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C. Practice Parameter update: Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): Obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology*. 2009; 73:126-32.

Harden CL, Pennell PB, Koppel BS, **Hovinga CA**, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50:1247-55.

Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, **Hovinga CA**, Wilner AN, Vazquez

B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50(5):1237-46.

Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Allen Hauser W, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, **Hovinga CA**, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsia*. 2009; 50:1229-36.

Asato MR, Manjunath R, Seth RD, Phelps SJ, Wheless JW, **Hovinga CA**, Pina-Garza JE, Haskins LS, Zingaro WM. Adolescent and caregiver experiences in epilepsy. *Journal of Child Neurology*. 2009; 24:562-71.

Wheless JW, Clarke D, **Hovinga CA**, Ellis M, Durmeier M, McGregor A, Perkins F. Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study *Journal of Child Neurology*. 2009; 24:946-51.

Amlie-Lefond C, deVeber G, Chan A, **Hovinga CA**, Benedict S, Bernard T, Carpenter S, Dowling M, Fullerton H, Kirkton A, Lo W, Carpenter J, Zamel K, Ichord R. International Pediatric Stroke Study. Use of tPA in Childhood Arterial Ischemic Stroke. *Lancet Neurology*. 2009; 8:530-6.

Amlie-Lefond C, Chan AK, Kirkton A, deVeber G, **Hovinga CA**, Ichord R, Stephens D, Zaidat OO. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial. *Neuroepidemiology*. 2009; 32: 279-86.

Hovinga CA Pennell PB. Antiepileptic drugs therapy in pregnancy II: fetal and neonatal exposure. *International Review of Neurobiology*. 2008; 83: 241-58.

Pennell PB, **Hovinga CA**. Antiepileptic drugs therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. *International Review of Neurobiology*. 2008; 83: 227-40.

Whelan HT, Cook JD, Amlie-Lefond C, **Hovinga CA**, Chan A, Ichord RN, deVeber G. Practical model-based dose-finding study in early phase clinical trials: Optimizing tPA dose for treatment of ischemic stroke in children. *Stroke*. 2008; 39:2627-36.

Wheless JW, Asato MS, Sheth RD, **Hovinga CA**, Phelps SJ, Pina-Garza JE, Manjunath R, Haskins LS. Seizure Emergency Plans: Results from a Cross Sectional-Epilepsy Survey. *Epilepsy Behav*. 2008; 13: 489-93.

Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, Pina Garza JE, Zingaro WM, Haskins LS. Association of Non-Adherence to Anti-Epileptic Drugs and Seizures, Quality of Life, and Productivity: Survey of Patients with Epilepsy and Physicians. *Epilepsy & Behavior*. 2008; 13: 316-22.

Hovinga CA, Ravina BR, DeProspero N, Bain L, Blumenstein R, Tobin A. Sytematic Evaluation of Therapeutics for Huntington's Disease (SET-HD): A Systematic Assessment for Neuroprotective Agents. <http://www.huntingtonproject.org/Default.aspx?tabid=50>

Girish H, Kotagal P, **Hovinga CA**, Wyllie E, Morris H. Carbamazepine Elevation in A Group of Patients and the Role of Fentanyl. *Seizure*. 2005; 14:312-7.

Hovinga CA. Valroce mide (Teva/Acorda). *Current Opinion in Investigational Drugs*. 2004; 5:101-6.

Lardizabal DV, Luders HO, **Hovinga CA**, Bourgeois BF. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. *Neurology*. 2004; 62:161.

Srikijvilaikul T, Najm IM, **Hovinga CA**, Gonzalez-Martinez J, Bingaman WE. Seizure Outcome Following Temporal Lobectomy In Temporal Lobe Cortical Dysplasia. *Epilepsia*. 2003; 44:1420-4.

Ravina BM, Fagan SC, Hart RG, **Hovinga CA**, Murphy DD, Marler JR. Neuroprotective Agents for Clinical Trials in Parkinson's Disease: A Systematic Assessment. *Neurology*. 2003; 60:1234-40.

Lazdizabal DV, Morris HH, **Hovinga CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. *Epilepsia*. 2003; 44:536-9.

Hovinga CA. SPM-927 (Schwarz Pharma). *IDrugs*. 2003; 6:479-85.

Hovinga CA. Erlosamide. *IDrugs (Iddb)-Ashley Publishing*. <http://iddb.com>, Accessible March 3, 2003.

Hovinga CA, Rose DF, Phelps SJ. Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital. *Journal of Pediatric Pharmacology and Therapeutics* 2003; 8:200-9.

Hovinga CA. Invited Review-Promising Investigational Anticonvulsant Drugs. *Expert Opinion on Investigational Drugs*. 2002; 10:1387-406.

Hovinga CA. Levetiracetam: A Novel Antiepileptic Medication. *Pharmacotherapy*. 2001; 21:1375-88.

Chaffin CC, **Hovinga CA**, Phelps SJ. Clonidine in the Treatment Attention- Deficit Hyperactivity Disorder. *Journal of Pediatric Pharmacy Practice* 1999; 4: 308-315.

Hovinga CA, Chicella MF, Rose DF, Eades SK, Dalton JT, Phelps SJ. Use of Intravenous Valproate in Three Pediatric Patients with Nonconvulsive or Convulsive Status Epilepticus. *Annals of Pharmacotherapy* 1999; 33: 579-584.

Phelps SJ, **Hovinga CA**, Rose DF, Vaughn C, Olsen-Creasy K. The Ketogenic Diet in Pediatric Epilepsy. *Nutrition in Clinical Practice* 1998; 13(6): 267-282.

Books & Chapters

Hovinga CA. Principals of Pharmacokinetics and Pharmacogenomics of Anticonvulsants. *Advances in*

the Treatment of Epilepsy. 1st Ed. Baumgartner JE, Wheless JW, Ed. New York, NY: Elsevier. 2008.

Phelps SJ, **Hovinga CA**, Wheless JW. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 7th ed. New York, NY: McGraw Hill. 2008.

Phelps SJ, **Hovinga CA**, Boucher BA. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 6th ed. New York, NY: McGraw Hill. 2006.

Hovinga CA, Lachhwani D. Treatment of Epilepsy. In: Moodie D, Sabella D, eds. The Cleveland Clinic Comprehensive Pediatric Board Review Book, 2nd Ed.. New York, NY. Lippincott Williams and Williams, 2005.

Hovinga CA, Wyllie E. Treatment of Epilepsy. In: Moodie D, Sabella D, eds. The Cleveland Clinic Comprehensive Pediatric Board Review Book. New York, NY. Lippincott Williams and Williams, 2002.

Phelps SJ, **Hovinga CA**, Boucher BA. Status Epilepticus. In: Dipiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 5th ed. New York, NY: McGraw Hill, 2002.

Hovinga CA. Antiepileptics, Anti-microbials, Opioid Monographs. In: Phelps SJ, ed. Guidelines for Administration of Intravenous Medications to Pediatric Patients, AJHP, 2001.

Hovinga CA, Phelps SJ. Attention Deficit Disorder. In: Herfinal E, Gourley D, eds. Textbook of Therapeutics; Drug and Disease Management, 7th ed. Baltimore, MD: Williams & Williams. May 2000.

Hovinga CA, Phelps SJ. Pediatric Epilepsy. In: Heusman B, ed. Pediatric Care Module. Pharmacotherapy Self-Assessment Program III. Kansas City, MO: American College of Clinical Pharmacy. January 2000.

Non-peer-reviewed publications

Hovinga CA. Anticonvulsant Mechanisms of Action. Neurospark, July 2011.

Hovinga CA. Medication Dosing in Pediatric Patients, A Careful Look at the Therapeutic Orphan. Neuroscience Pathways, March 2003.

Hovinga CA. What is All the Fuss about Ritalin? JPPT. 2001; 37:304-5.

Hovinga CA. Antiepileptic Drug Approval In Children: Where Are We Now?. American Epilepsy Society News. 2001; 10:1-6.

Hovinga CA. Role of Carnitine Supplementation During Valproate Therapy. Cleveland Foundation Epilepsy Newsletter, Spring 2001 Edition.

Hovinga CA. Singulair-A New Drug for Asthma. Le Bonheur Capsule 1998 Spring Edition.

Hovinga CA. Topiramate. Le Bonheur Capsule 1997 Fall Edition.

Non-print / Online materials

Hovinga CA. Acetazolamide. In: Panayiotopoulos C., ed. Atlas of Epilepsies. <http://www.springer.com>, 2009.

Hovinga CA. Systematic Evaluation of Treatments for Huntington's Disease. <http://www.huntingtonproject.org/Default.aspx?tabid=50>

Hovinga CA. Advances in the Treatment of Epilepsy. ASHP Annual Meeting Course 2004. Published <http://ashp.omnibooksonline.com/2004/papers/PI-166.pdf>, Program #204-000-04-262-L01.

Hovinga CA. New Agents in the Treatment of Pediatric Epilepsy. ASHP Annual Meeting Course 2004. Published <http://ashp.omnibooksonline.com/2004/papers/PI-117.pdf>, Program #204-000-04-243-L01.

Invited Reviews

Pharmacotherapy Self-Assessment Program: Neurology Module 4th Edition by American College of Clinical Pharmacy, 2001-2002.

Natural Products Explorer CD-ROM, 1th Edition by Facts & Comparisons. Doody Publishing 2000.

Medicinal Chemistry Tutorial, 1st Edition. by Roche V. Doody Publishing, 2000.

Pediatric Dosage Handbook 1999-2000, 6th Edition by Taketomo CK, Hodding JH, Kraus DM. Doody Publishing, 1999.

Ad Hoc Reviewer

ACCP PSAP Pediatric Review Board

Annals of Pharmacotherapy

Expert Opinion in Investigational Drugs

iDrugs

Journal of Pediatric Pharmacotherapy (and Board of Technical Consultants)

Journal of Pharmacy Technology

Lancet Neurology

Pediatric Neurology

Pharmacotherapy

INVITED PRESENTATIONS

International

Institute for Advance Clinical Trials in Children: Update MICYRN General Assembly . Ottawa, Canada.	December 6, 2019
Institute for Advanced Clinical Trials in Children-Update on the US Perspective, C4C Launch Meeting , Berlin, Germany.	May 15, 2018
SET-HD: Rationale and Progress. European Huntington's Disease (Euro-HD) Network , Aachen, Germany.	Jan. 30, 2005
SET-HD: High Output Screening in Neurodegenerative Diseases. Euro- HD Network , Aachen, Germany.	Jan. 29, 2005
National	
The Adolescent Landscape. Pediatric Innovation and Research Forum. Bethesda, MD	October 15, 2019
Learning Networks Applied to Pediatric Clinical Trials, I-ACT for Children's Design Meeting , Chicago, IL	Mar 28, 2019
Pediatric Device Trials: Where are We Know?, SOCRA Pediatric Conference , St. Pete Beach, CA.	Feb. 27, 2019
Pediatric Research Innovation, PPHNet Annual Meeting , San Francisco, CA	Feb. 2, 2019
The Duchenne Muscular Dystrophy Platform Trial (DPT), Parent Project Muscular Dystrophy Annual Meeting , Orlando FL.	Jan. 20, 2018
Use of Cannabidiol in Pediatric Epilepsy: Current Evidence. American Society of Health-System Pharmacy Midyear Meeting . Orlando, FL.	Dec. 5, 2017
Counseling Women with Epilepsy on the use of Anti-Epileptic Drugs during Pregnancy. American Colleges of Clinical Pharmacy Annual Meeting . Phoenix, AZ.	Oct. 9, 2017
Toxin Safety Zone for Patients and Practitioners: A Practice Safety Review for Providers Injecting any Pediatric and Adolescent Hypertonia. American Academy of Physical Medicine and Rehabilitation Annual Assembly . New Orleans, LA.	Oct. 21, 2017
Toxin Safe Territory for Both Patients and Providers. American Academy for Cerebral Palsy and Developmental Medicine . Annual Meeting. Austin, TX.	Sept. 23, 2017
How to Incorporate Research into Child Practice. Child Life Council	May 24, 2015

Annual Conference on Specialty Issues. Cincinnati, OH.

- Neurology Board Review. **Pediatric Pharmacy Advocacy Group Annual Meeting**, Minneapolis, MN. May 1, 2015
- Autism Spectrum Disorders: Update on Diagnosis and Treatment. **American College of Clinical Pharmacy Annual Meeting**. Hollywood, FL. Oct. 23, 2012
- New Anticonvulsants and Their Role in Pediatric Epilepsies. **American Society of Health-System Pharmacists Midyear Meeting**. Anaheim, CA. Dec. 7, 2010
- The Pharmacogenomics of the New Generation Antiepileptics as They Relate to Different Pediatric Patients (from Neonate to Adolescent). **American College of Clinical Pharmacy Annual Meeting**. San Antonio, TX. Oct. 19, 2010
- Pharmacogenomics of Pediatric Epilepsy. **Pediatric Pharmacy Advocacy Group Spring Meeting**. Salt Lake, UT. Apr. 16, 2010
- Update on the Pharmacotherapy of Pediatric Epilepsy. **American College of Clinical Pharmacy Spring Meeting**. Phoenix, AZ. Apr. 8, 2008
- Anticonvulsants and Fertility, Pregnancy and Lactation. **American College of Clinical Pharmacy Annual Meeting**. Denver, CO. Oct. 14, 2007
- Neonatal Clinical Trials and Pharmacology. Workshop in Neonatal Seizure Trials. **NIH/NINDS**. Bethesda, MA.
- Ups and Downs of Anticonvulsant Therapy. Clinical Controversies in the Epilepsy Monitoring Unit. Professionals in Healthcare Symposium. **The American Epilepsy Society and American Neurophysiology Society Annual Meeting**. Dec. 2, 2005
- Systematic Evaluation of Treatments for Huntington's Disease. The HD Therapeutics Pipeline: From Drug Discovery to Clinical Trials Symposium. **Presented at the NIH/NINDS Study Section**. Philadelphia, PA. Oct. 19, 2005
- Disease Modification Therapy for Neurodegenerative Disease. **Potential Therapies for Huntington's Disease Conference**. HiQ Foundation, New York City, NY. Aug. 24, 2005
- Advances in the Treatment of Epilepsy. **American Society of Health-System Pharmacists Annual Meeting**, Orlando, FL. Dec. 8, 2004

Use of the New Anticonvulsants in Children. PPAG Symposium, American Society of Health-System Pharmacists Annual Meeting , Orlando, FL.	Dec. 9, 2004
Translational Research In Neuroprotection Antiepileptogenesis. American Epilepsy Society Annual Meeting . New Orleans, LA.	Dec. 6, 2004
Systematic Evaluation of Treatments for Huntington's Disease (SET- HD): Updates of the First 10 Compounds. Presented at the NIH/NINDS Study Section Meeting . St. Louis, MO.	Nov. 4, 2004
Clinical Neurology Pediatric Annual Conference XXV , Miami Children's Hospital Brain Institute, Miami, FL	May 8, 2004
Neuroprotection in Parkinson's Disease. CINAPS. American College of Clinical Pharmacy . Atlanta, GA.	Nov. 4, 2003
New Antiepileptic Drug Therapy: A Decade Later. Where Are We Now? Ohio College of Clinical Pharmacy. Cleveland, OH.	Oct. 8, 2003
Pharmacotherapy of Attention Deficit Hyperactivity Disorder. Pediatric Advocacy Annual Conference . Dana Point, CA.	Oct. 3, 2003
Treatment of Refractory Neonatal Seizures. Pediatric Pharmacology Advocacy Group Neonatal Specialty Conference . Tucson, AZ.	Apr. 6, 2002
Neurodevelopment of the Preterm Neonate. Pediatric Pharmacology Advocacy Group Neonatal Specialty Conference . Tucson, AZ.	Apr. 6, 2002
Treatment of Status Epilepticus. Medical College of Georgia, Grand Rounds . Augusta, GA.	Mar. 10, 2003
Pediatric Neuroprotection: Mini-Sabbatical Experience. CNS PRN , American College of Clinical Pharmacy , Fall Meeting. Albuquerque, NM.	Oct. 21, 2002
Can Medications Prevent Epilepsy? Pediatric Pharmacotherapy Advocacy Group , Annual Meeting. St Petersburg, FL.	Oct. 2, 2002
Molecular Mechanisms of Drug Resistance in Epilepsy. Bethel- Cleveland Clinic Foundation International Symposium . Cleveland, OH.	May 19, 2002
Antiepileptic Drug Use in Women with Epilepsy: Case Studies-Panel. Cleveland Clinic Foundation Comprehensive Course . Painesville, OH.	May 18, 2002

Drug Interactions: Case Studies-Panel. Cleveland Clinic Foundation Comprehensive Course. Painesville, OH.	May 18, 2002
Developmental Pharmacokinetics of Antiepileptic Medications. Cleveland Clinic Foundation Comprehensive Course. Painesville, OH.	May 18, 2002
Side Effects of Antiepileptic Medications: Case Studies. Cleveland Clinic Foundation Comprehensive Course. Painesville, OH.	May 17, 2002
Antiepileptic Medications in Clinical Practice. Neuroscience National Symposium. Cleveland, OH.	Nov. 14, 2001
Antiepileptic Medication Selection: Case Studies. Ohio College of Clinical Pharmacy, Independence, OH.	May 4, 2001
New Antiepileptic Medications. Ohio College of Clinical Pharmacy, Independence, OH.	May 4, 2001
A Practical Approach to the Ketogenic Diet. American Society of Parental and Enteral Nutrition Annual Meeting, Nashville, TN.	Jan. 24, 2000
Regional	
Neonatal Seizures and Stroke, Northern Ohio Neonatal Nursing Symposium. Westlake, OH.	Oct. 16, 2006

OTHER PRESENTATIONS, POSTERS, AND ABSTRACTS

International

Wittenberg BA, Johnson J, Wirth K, Hovinga C. Inclusion of Family Advisors as Primary Investigators in Research Studies. The 6th International Conference on Patient-and Family-Centered Care in Vancouver, British Columbia, Canada. Abstract #0298-000318.	Aug. 7, 2014
---	--------------

National

Hovinga C, Berry S, Larkindale J, Bronson A, Litvinchuk D, Ascheim D, Connor E. Improving Clinical Trials in Duchenne Muscular Dystrophy By Using A Novel Platform Study Approach., MDA Foundation Clinical and Scientific Annual Meeting. Orlando, FL, Abstract 41.	July 2019
---	-----------

Hovinga C, Benson L BS, Allen J, McConoughey S, O'Brien V,	Feb. 2019
---	-----------

Connor E, Survey of Pediatric Device Trial Experience Within the I-ACT for Children Research Network. SOCRA Pediatric Conference, St. Pete, CA, Abstract 2.1

Hovinga C, Berry S, Larkindale J, Bronson A, Litvinchuk D, Ascheim D, Connor E. Improving Clinical Trials in Duchenne Muscular Dystrophy By Using A Novel Platform Study Approach., Parent Project Muscular Dystrophy. Clinical Meeting. Orlando, FL, Abstract 23. Jan. 2018

Titus JB, **Hovinga C**, Kime K, Bower N, Perkins F, Clarke D. Physicians' Perspectives in Utilizing Neuropsychological Services in Pediatric Patients With Epilepsy. American Epilepsy Society Annual Meeting. San Diego, CA. Abstract 2.291. Dec. 2012

Watson M, Clarke DF, **Hovinga C**, Nussbaum N. The Use of Passive Functional MRI in Presurgical Planning for Pediatric Patients with Epilepsy. American Epilepsy Society Annual Meeting. San Diego. Abstract 2.161. Dec. 2012

Hovinga CA, Kime K, Bower NR, Titus JB, Perkins FF, Clarke DF. Knowledge of Physicians and Practice Parameters Pertaining to the Diagnosis and Drug Management of Pediatric Epilepsy. American Epilepsy Society Annual Meeting. San Diego. Abstract 1.343. Dec. 2012

Perkins F, Kime K, Bower N, **Hovinga CA**, Titus JB, Clarke DF. Physicians Practices for Epilepsy Surgery in Pediatrics. American Epilepsy Society Annual Meeting. San Diego. Abstract 1.342. Dec. 2012

Pickel SF, Shen MW, **Hovinga CA**. Look Who's Talking: A Comparison of Perceptions Versus Objective Observations During Family Centered Rounds. Pediatric Academic Society. Boston, MA. Abstract 3821.301. Apr. 30, 2012

Tylavsky F, **Hovinga C**, Murphy L, Graff C, Palmer F, Thomas F, Park V, Connor P, Volgyi E, Adkins R, Krushkal J. Genetic and Epigenetic Analysis of Early Childhood Phenotypic Outcomes in a Community-Based Longitudinal Cohort in Memphis, TN: The CANDLE Study. Heidelberg, Germany. *Genetic Epi.* 2012;36:159. Sept. 2011

Pont SJ, Sage WM, Ripley , Millea S, Rao M, **Hovinga CA**, Kelder SH. Mapping Child Fitness and Obesity: Leveraging data sharing and public reporting to mobilize system change. Platform. Austin, TX Annual Conference of the International Society for Behavioral Nutrition and Physical Activity (ISBNPA). May 25, 2012

Manjunath R, Asato M, Wheless J, Sheth R, **Hovinga C**, Phelps S, Pina-Garza E, Haskins L , Zingaro W. Burden of Epilepsy In Adolescents and Dec. 2008

Their Care Givers. American Epilepsy Society Annual Meeting. Seattle, WA.. *Epilepsia*. 2008; 49: 165.

Wheless J, **Hovinga C**, Clarke D, McGregor A, Perkins F, Durmeier M. Dec. 2008
Rapid Infusion of Loading Dose of Intravenous Levetiracetam with Minimal Dilution: A Safety Study. American Epilepsy Society Annual Meeting. Seattle, WA. *Epilepsia*. 2008; 49: 109.

Hovinga CA*, Foldvary-Shaefer N, Syed T, Riley J. Lamotrigine Dec. 2007
Pharmacokinetics in Lactation and in the Neonate. American Epilepsy Society Annual Meeting. Seattle, WA. *Epilepsia*. 2008; 49: 97.

Foldvary-Shaefer N, **Hovinga CA**, Riley J, Syed T, Suciu GP. Dec. 2007
Pharmacokinetics of Lamotrigine in Pregnancy: Correlation of Serum and Salivary Concentrations. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 337.

Wheless JW, Asato MS, Sheth RD, **Hovinga CA**, Phelps SJ, Pina-Garza Dec. 2007
JE, Manjunath R, Haskins LS. Prevalence and Description of Seizure Plans in Adult US Population. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 342.

Hovinga CA*, Asato MS, Sheth RD, Wheless JW, Phelps SJ, Pina-Garza Dec. 2007
JE, Manjunath R, Haskins LS. Impact of Non-Adherence to Anti-Epileptic Drugs on Seizure Activity, Quality of Life, and Productivity. American Epilepsy Society Annual Meeting. Philadelphia, PA. *Epilepsia*. 2007; 48: 333.

Phelps SJ, Asato MR, Wheless JW, **Hovinga CA**, Pina-Garza JE, Dec. 2007
Manjunath R, Haskins LS. Comparison of Neurologists and Patient Perceptions of Adherence of Epilepsy. American Epilepsy Society Annual Meeting. Philadelphia, PA.. *Epilepsia*. 2007; 48: 334.

Hovinga CA*, Phelps SJ, Asato MS, Sheth RD, Wheless JW, Pina-Garza Dec. 2007
JE, Manjunath R, Haskins LS, Zingaro W. Neurocognitive and Behavioral Factors Associated with Antiepileptic Drug Nonadherence. American College of Clinical Pharmacy Annual Meeting. *Pharmacotherapy*. 2007; 29:1497

Donald D, **Hovinga CA**, Lee K, Bobo K. Evaluation of Enoxaparin in Mar. 31, 2007
Pediatric Patients. Pediatric Pharmacology Midyear Meeting. Austin, TX.

Sahni J, **Hovinga CA**, Lee K. Aprotinin in Pediatric Cardiopulmonary Mar. 31, 2007
Bypass. Pediatric Pharmacology Midyear Meeting. Austin, TX.

Lefond CA,, Chan A, **Hovinga CA**, DeVeber G, Ichord B. Feb. 16, 2007

Thrombolysis in children with arterial ischemic stroke: International results from the International Pediatric Stroke Study. International Stroke Conference 2007, Kissimmee, FL.

Ravina B, DiProspero N,, Fagan SC, Fischbeck K, Harrison M , Hart R, Heemskerk J, Murphy D, Profenno L, Blumenstein R, Signer ER, Taylor P, Tretheway JA,. **Hovinga CA**. Systematic Evaluation of Treatments for Huntington's Disease (SET-HD): An Interim Report. Presented as a platform at HD 2004: Changes, Advances and Good News (CAG)n" to the Hereditary Disease Foundation Annual Meeting, Boston, MA. Aug. 15, 2004

Hovinga CA*, Loddenkemper T, Holland KD, Chapman K, Shigeto H, Burrier C, Kellinghaus C. Assessment of the Antiepileptogenic Properties of Lamotrigine in a Hippocampal Stimulation Model of Prolonged Status Epilepticus. American Epilepsy Society Annual Meeting, Boston, MA. *Epilepsia*. 2003; 44 (Suppl. 9):201. Dec. 10, 2004

Hovinga CA*. Efficacy and Safety of Levetiracetam in Children: A 2-Year Experience. Presented at the American College of Clinical Pharmacy Annual Meeting, Atlanta, GA. Nov. 3, 2003

Srikijvilaikul T, **Hovinga CA**, Bingaman WE, Najm IM. Seizure Outcome Following Temporal Lobectomy in Temporal Lobe Cortical Dysplasia. Presented Annual Meeting of the American Epilepsy Society Annual Meeting, Seattle, WA. Dec. 11, 2002

Serje A, **Hovinga CA**, Morris H, Merner K. A Pharmacokinetic Based Method for Conversion of Patients from Valproate to Lamotrigine Monotherapy. Presented Annual Meeting of the American Epilepsy Society Annual Meeting, Seattle, WA. Dec. 9, 2002

Hovinga CA*, Morris H, Holland K, Foldvary N, Kotagal P, Wyllie E. Levetiracetam's Efficacy in Adults and Children. Platform presentation at Annual Meeting of the American Epilepsy Society Annual Meeting, Philadelphia, PA. *Epilepsia* 2001; 42 (Suppl 7). F.08. Dec. 4, 2001

Lazdizabal DV, Morris HH, **Hovinga, CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. Presented at Neuroscience Research Day, Cleveland Clinic Foundation, Cleveland, OH. May 14, 2001

Lazdizabal DV, Morris HH, **Hovinga CA**, Carreno M. The Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. *Neurology*. 56 (Suppl. 3): A333. Apr. 2001

Girish H, Kotagal P, **Hovinga CA**, Wyllie E, Morris H. Carbamazepine Apr. 2001

Elevation in A Group of Patients and the Role of Fentanyl., *Neurology*. 2001; 56 (Suppl. 3): A236.

Hovinga CA*, Rose DF, Phelps SJ. Appropriateness of Anticonvulsant Level Monitoring in A Pediatric Hospital. Poster presentation at the Annual Meeting of the American Epilepsy Society Annual Meeting, Orlando, FL. *Epilepsia* 1999; 40 (S7):121. Dec. 1999

Hovinga CA*, Chicella M, Rose DF, Eades SK, Dalton J, Phelps SJ. Use of Intravenous Valproate In Two Pediatric Patients With Convulsive Status Epilepticus, presentation PPAG Annual Clinical Meeting, Kiawah Island, SC. *Journal of Pediatric Pharmacy Practice* September/October 1998. Oct. 1998

Hovinga CA*, Shinn B. Student vs. Preceptor Assessments During Fourth-Year Clinical Experiences, Poster presentation at the ASHP MidYear Clinical Meeting, New Orleans, LA.. *AJHP* December 1996 Dec. 1996